Shire, Arrowhead join forces to develop peptide-targeted therapeutics
Under the agreement, Arrowhead will receive research funding and could be eligible for development, regulatory and commercialization milestone payments of approximately $32.8m for each development candidate, an additional
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.